Nabriva (NBRV)

Nabriva Stock Analysis & Ratings

NBRV Stock Chart & Stats

Day’s Range$0.2 - $0.213
52-Week Range$0.19 - $2.32
Previous Close$0.21
Average Volume (3M)461.62K
Market Cap$12.95M
P/E Ratio-0.2
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A
EPS (TTM)-0.93



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Nabriva’s price range in the past 12 months?
Nabriva lowest stock price was $0.19 and its highest was $2.32 in the past 12 months.
    What is Nabriva’s market cap?
    Nabriva’s market cap is $12.95M.
      What is Nabriva’s price target?
      The average price target for Nabriva is $2.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 876.09% Increase from the current price of $0.205.
        What do analysts say about Nabriva?
        Nabriva’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Nabriva’s upcoming earnings report date?
          Nabriva’s upcoming earnings report date is Aug 11, 2022 which is in 84 days.
            How were Nabriva’s earnings last quarter?
            Nabriva released its earnings results on May 05, 2022. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.01.
              Is Nabriva overvalued?
              According to Wall Street analysts Nabriva’s price is currently Undervalued.
                Does Nabriva pay dividends?
                Nabriva does not currently pay dividends.
                What is Nabriva’s EPS estimate?
                Nabriva’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Nabriva have?
                Nabriva has 63,200,000 shares outstanding.
                  What happened to Nabriva’s price movement after its last earnings report?
                  Nabriva reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -10.345%.
                    Which hedge fund is a major shareholder of Nabriva?
                    Currently, no hedge funds are holding shares in NBRV


                    Nabriva Stock Analysis

                    Smart Score
                    Not Ranked
                    Price Target
                    ▲(876.09% Upside)
                    Moderate Buy
                    This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                    Learn more about TipRanks Smart Score

                    Company Description


                    Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

                    Similar Stocks
                    Price & Change
                    Paratek Pharmaceuticals

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis